中国药物警戒 ›› 2020, Vol. 17 ›› Issue (1): 31-36.
DOI: 10.19803/j.1672-8629.2020.01.07

• 法规与管理研究 • 上一篇    下一篇

基于真实世界的磷酸奥司他韦口服制剂流感暴发期临床应用评价

王璐1, 陈陶1, 张程亮1, 尹先国2, 赵丽2, 刘东1   

  1. 1华中科技大学同济医学院附属同济医院药学部,湖北 武汉 430000;
    2湖北省药品（医疗器械）不良反应监测中心,湖北 武汉 430000
  • 收稿日期:2018-11-19 修回日期:2020-01-15 出版日期:2020-01-15 发布日期:2020-01-15
  • 通讯作者: *刘东,男,主任药师,临床药学。E-mail:ld2069@outlook.com
  • 作者简介:王璐,女,药师,临床药学。
  • 基金资助:
    湖北省药品（医疗器械）不良反应监测中心课题（20170314）

Evaluation of Clinical Application of Oral Oseltamivir Based on Real-world during the Height of Influenza Outbreak

WANG Lu1, CHEN Tao1, ZHANG Chengliang1, YIN Xianguo2, ZHAO Li2, LIU Dong1   

  1. 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei 430000, China;
    2Hubei Center for ADR Monitoring, Wuhan Hubei 430030, China
  • Received:2018-11-19 Revised:2020-01-15 Online:2020-01-15 Published:2020-01-15

PDF (PC)

306

摘要： 目的 了解流感暴发期磷酸奥司他韦口服制剂在住院真实世界人群中的应用情况及临床安全性,为临床合理应用提供参考。方法 采取回顾性、多中心监测方式,收集湖北省6家医院2017年1月1日-2017年4月30日使用磷酸奥司他韦的住院患者,对用药人群特征、用药信息及不良反应（ADR）进行总结分析。结果 共收集用药患者1 327例,其中3岁以下儿童占比32.71%;用药科室主要分布在儿科、呼吸与危重症医学科、感染科;平均用药天数为3.97 d;不良反应9例（0.68%）。结论 磷酸奥司他韦口服制剂临床使用广泛,安全性相对较高,但仍需规范其临床应用,减少或避免ADR发生,保障用药安全。

关键词: 磷酸奥司他韦口服制剂, 真实世界, 临床应用, 安全性

Abstract: Objective To observe the clinical application and safety of oral oseltamivir in hospitalized patients in the real-world during the height of an influenza outbreak, and to make recommendations for clinical application. Methods During this multi-center and retrospective research, all the information was collected from patients from six hospitals in Hubei Province who had taken oseltamivir between January 1, 2017 and April 30, 2017. The data on these patients was analyzed with specific focus on demographic characteristics, medical information and adverse reactions (ADRs). Results A total of 1 327 cases were collected, about 32.71% of whom were children under 3. Oral oseltamivir was prescribed mainly by departments of pediatrics, respiratory diseases and infections. The mean time of medication was 3.97 days. Only 9 cases recorded ADRs(0.68%). Conclusion Oral oseltamivir is widely used in clinical practice, and it is relatively safe. However, its clinical application needs to be standardized in order to reduce or prevent ADRs and ensure the safety of drug use.

Key words: oral oseltamivir, real-world, clinical application, safety

中图分类号: